Podium to Practice: EHA 2025 – Multiple Myeloma: LONG-TERM REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RRMM

Podium to Practice: EHA 2025 – Multiple Myeloma: LONG-TERM REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RRMM

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Irwin Sandhu

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

S192 – LONG-TERM (≥5 YEAR) REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Studies/trials discussed:

S192 – LONG-TERM (≥5 YEAR) REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Tagged